Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Cancer Discovery|2022Cited by 139
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H. Strand, Graham A. Colditz, Belén Rivero‐Gutiérrez et al.|Cancer Cell|2022Cited by 88
Denosumab for treatment of breast cancer bone metastases and beyondJulie R. Nangia, Meghana V. Trivedi, D. Joseph et al.|Expert Opinion on Biological Therapy|2012Cited by 5
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Beom-Jun Kim et al.|Unknown|2023Cited by 0